| Nov 13 |
BioNTech to Acquire Biotheus to Boost Oncology Strategy
|
| Nov 13 |
BioNTech to buy Biotheus, gaining control of cancer bispecific
|
| Nov 9 |
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
|
| Nov 8 |
What Analysts Are Saying About BioNTech Stock
|
| Nov 8 |
BioNTech upgraded to buy at Goldman Sachs on tumor asset
|
| Nov 6 |
Vaccine Stocks Drop on Worries About an RFK Jr. Role
|
| Nov 6 |
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
|
| Nov 6 |
Results: BioNTech SE Confounded Analyst Expectations With A Surprise Profit
|
| Nov 5 |
BioNTech’s Q3 2024: Strong Revenue and Oncology Progress
|
| Nov 5 |
BioNTech SE Reports Strong Revenue Growth Amid Rising R&D Costs
|
